SHINE, SRNL Agree To Exclusive License Agreement

Shine Medical Technologies and Savannah River Nuclear Solutions, the operating contractor for the Department of Energy’s Savannah River National Laboratory, announced yesterday an agreement to allow an exclusive license on SRNL’s patented hydrogen isotope separation process for use in SHINE’s medical isotope production. According to a release, the agreement gives SHINE the right to use SRNL’s thermal cycling absorption process (TCAP) in its manufacturing facility. The TCAP provides the high-purity inputs needed for SHINE’s patented technology, which enhances the production of medical isotopes, including molybdenum-99. “We are extremely pleased to have the opportunity to contribute to solving the global problem of medical isotope shortages.  SHINE’s isotope manufacturing plant will be a game-changer for U.S. patients and we’re proud to be part of making that happen,” SRNL Director Terry Michalske said in a statement. SHINE CEO Greg Piefer added, “Savannah River National Laboratory has put a tremendous amount of effort into developing and refining the TCAP technology and we’re excited to take advantage of this proven, state-of-the-art technology in our facility.”